Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2012-09-20

Clinical Trial Update: Evaluating The Safety Of Exemestane Following 2-3 Years Of Adjuvant Tamoxifen Therapy In Postmenopausal Early Breast Cancer Patients

View source ↗

Summary

A terminated clinical trial evaluating the safety of exemestane after 2-3 years of adjuvant tamoxifen in postmenopausal patients with early breast cancer; resul…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Aromasin (exemestane)

Snippet

Sponsor: Pfizer | Conditions: Early Breast Cancer | Status: TERMINATED | Results posted: 2012-09-20